Search results for "ALAT"

showing 10 items of 4241 documents

Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline viro-immunological status and outcome in patients under first-line ART

2018

Objectives We evaluated the association between pre-ART HIV DNA and HIV-infected participant characteristics at baseline as well as with their response to first-line ART. Methods Four hundred and thirty-three patients from the ICONA cohort, starting first-line ART after the year 2000, were analysed. Pre-ART HIV DNA was quantified with the modified COBAS TaqMan HIV-1 Test and normalized by CD4+ T cells. Linear correlation between pre-ART HIV DNA and other continuous markers (HIV RNA, CD4 count, markers of inflammation and coagulation) at baseline was evaluated by means of Pearson correlation coefficient and a linear regression model. Survival analyses and Cox regression models were used to s…

0301 basic medicineOncologyCD4-Positive T-LymphocytesMaleHIV InfectionsSettore MED/07chemistry.chemical_compoundHIV InfectionPharmacology (medical)ViralProspective StudiesProspective cohort studyAntiinfective agentAdult; Anti-Retroviral Agents; CD4-Positive T-Lymphocytes; DNA Viral; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Prospective Studies; Survival Analysis; Treatment Outcome; Viral LoadMiddle AgedViral LoadvirologyHIV CD4Stavudinemedicine.anatomical_structureInfectious DiseasesTreatment Outcomehiv-1 t-lymphocytes virology blood hiv rna hiv dnaAnti-Retroviral AgentsCD4-Positive T-Lymphocyteblood hiv rnaCohorthiv dnaFemaleSurvival AnalysiViral loadARTHumanMicrobiology (medical)Adultmedicine.medical_specialtyAntiretroviral Therapy CD4 Lymphocyte Count StavudineT cellAntiretroviral TherapySettore MED/17 - MALATTIE INFETTIVENO03 medical and health sciencesInternal medicinemedicineHumanst-lymphocytesSurvival analysisPharmacologybusiness.industryProportional hazards modelHIVDNASurvival AnalysisCD4 Lymphocyte CountProspective Studie030104 developmental biologychemistryDNA ViralHIV-1Anti-Retroviral AgentbusinessDNA
researchProduct

A phase I dose-escalation of trifluridine/tipiracil in combination with oxaliplatin in metastatic colorectal cancer.

2017

TPS3626 Background: Trifluridine/tipiracil, also known as TAS‐102, is a combination of an antineoplastic thymidine‐based nucleoside analogue (trifluridine) and a thymidine phosphorylase inhibitor (tipiracil hydrochloride). The antitumor activity of combined trifluridine/tipiracil and oxaliplatin has been studied in gastrointestinal tumor xenografts, including a 5‐FU resistant subline, using a nude mouse model. This study demonstrated increased antitumor activity for the combination compared to trifluridine/tipiracil or oxaliplatin alone (p < 0.001) (Nukatsuka et al., Anticancer Res 2015). These data support the rationale for clinical use of the combination. We describe a phase 1, intern…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyNucleoside analogueColorectal cancerbusiness.industryTrifluridinemedicine.diseaseOxaliplatin03 medical and health scienceschemistry.chemical_compound030104 developmental biology0302 clinical medicineOncologychemistry030220 oncology & carcinogenesisInternal medicinemedicineDose escalationThymidine phosphorylasebusinessThymidinemedicine.drugTipiracilJournal of Clinical Oncology
researchProduct

A phase I study of nintedanib combined with cisplatin/gemcitabine as first-line therapy for advanced squamous non-small cell lung cancer (LUME-Lung 3)

2018

Abstract Background There are limited treatment options for squamous non-small cell lung cancer (sqNSCLC) and prognosis remains poor. The safety and pharmacokinetics (PK) of nintedanib, a triple angiokinase inhibitor, plus cisplatin/gemcitabine as first-line treatment for advanced sqNSCLC patients, were evaluated. Materials and methods A phase I, dose-escalation study administering drugs in a 21-day cycle: cisplatin (75 mg/m2, Day 1), gemcitabine (1250 mg/m2, Days 1 and 8) and nintedanib (Days 2–7, 9–21) were given for 4–6 cycles, followed by monotherapy until disease progression or adverse events (AEs). Two nintedanib doses were tested, 150 mg twice daily (bid) and 200 mg bid, to determine…

0301 basic medicineOncologyMaleCancer ResearchPHARMACOKINETICSIndolesLung NeoplasmsPACLITAXELDeoxycytidineANGIOGENESISSquamouschemistry.chemical_compound0302 clinical medicineNon-small cell lung cancerCarcinoma Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsBIBF 1120Aged 80 and overMiddle AgedPrognosisTreatment OutcomeOncologyPaclitaxelLABEL DOSE-ESCALATION030220 oncology & carcinogenesisNintedanibFemaleCLINICAL-PRACTICE GUIDELINESmedicine.drugPulmonary and Respiratory Medicinemedicine.medical_specialtyBevacizumabMaximum Tolerated DoseNintedanibBEVACIZUMABCONTROLLED-TRIALDisease-Free Survival03 medical and health sciencesPharmacokineticsInternal medicinemedicineHumansAdverse effectAgedNeoplasm StagingTRIPLE ANGIOKINASE INHIBITORCisplatinCARBOPLATINbusiness.industryGemcitabineCarboplatinGemcitabine030104 developmental biologychemistryCisplatinbusinessLung Cancer
researchProduct

Cardiovascular Issues in Tyrosine Kinase Inhibitors Treatments for Chronic Myeloid Leukemia: A Review

2021

Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm driven by a fusion gene, encoding for the chimeric protein BCR-ABL, with constitutive tyrosine kinase activity. The use of tyrosine kinase inhibitors (TKIs) has drastically improved survival, but there are significant concerns about cardiovascular toxicity. Cardiovascular risk can be lowered with appropriate baseline evaluation, accurate choice of TKI therapy, improvement of modifiable cardiovascular risk factors through lifestyle modifications, and prescription of drugs for primary or secondary prevention. Which examinations are necessary, and when do they have to be scheduled? How often should a TKI-treated patient undergo wh…

0301 basic medicineOncologycardiovascular riskmedicine.medical_specialtychronic myelocytic leukemiacardio-oncologyPhysiologyReviewSettore MED/15 - Malattie Del Sangue03 medical and health sciencescardiovascular events0302 clinical medicineInternal medicinePhysiology (medical)hemic and lymphatic diseasesmedicineNeoplasmQP1-981Medical prescriptionAdverse effectMyeloproliferative neoplasmHematologyMechanism (biology)business.industryMyeloid leukemiamedicine.diseaseSettore MED/11 - Malattie Dell'Apparato Cardiovascolarerespiratory tract diseasestyrosine kinase inhibitions therapy030104 developmental biology030220 oncology & carcinogenesiscardiovascular events chronic myelocytic leukemia cardiovascular risk cardio-oncology tyrosine kinase inhibitions therapybusinessTyrosine kinaseFrontiers in Physiology
researchProduct

Multidisciplinary surgical management of Cowden syndrome: Report of a case

2016

Cowden’s Syndrome (CS) is a rare congenital autosomal dominant disorder that affects around 1/200000 patients with an incomplete penetrance and variable expressivity, characterized by alterations in a tumor suppressor gene. A 14-year-old Caucasian male patient came to the attention of the authors complaining of palm nodules, gingival bleeding and painful pedunculated lesions on the lips and on the labial side of anterior sextants. After genetic investigation the final diagnosis of a Cowden Syndrome was made. The lesions were surgically removed under general anesthesia and no clinical signs of recurrence were found three months after surgical excision. Considering the severe symptoms of the …

0301 basic medicineOral papillomatosismedicine.medical_specialtyOdontologíaOral papillomatosisCancer predispositionSettore MED/28 - MALATTIE ODONTOSTOMATOLOGICHE03 medical and health sciences0302 clinical medicineCancer predisposition; Case report; Early diagnosis; Multiple hamartoma syndrome; Oral papillomatosis; Dentistry (all)Case reportmedicineGeneral Dentistrybusiness.industryCancer predispositionMultiple hamartoma syndromeMultiple hamartoma syndrome030206 dentistryCowden syndromeEarly diagnosismedicine.diseaseCiencias de la saludPenetranceDermatologySurgery030104 developmental biologyMale patientDentistry (all)UNESCO::CIENCIAS MÃ DICASOdontostomatology for the Disabled or Special PatientsSurgical excision:CIENCIAS MÃ DICAS [UNESCO]businessJournal of Clinical and Experimental Dentistry
researchProduct

Optimization of PMAxx pretreatment to distinguish between human norovirus with intact and altered capsids in shellfish and sewage samples

2018

Shellfish contamination by human noroviruses (HuNoVs) is a serious health and economic problem. Recently an ISO procedure based on RT-qPCR for the quantitative detection of HuNoVs in shellfish has been issued, but these procedures cannot discriminate between inactivated and potentially infectious viruses. The aim of the present study was to optimize a pretreatment using PMAxx to better discriminate between intact and heat-treated HuNoVs in shellfish and sewage. To this end, the optimal conditions (30 min incubation with 100 μM of PMAxx and 0.5% of Triton, and double photoactivation) were applied to mussels, oysters and cockles artificially inoculated with thermally-inactivated (99 °C for 5 …

0301 basic medicineOyster030106 microbiologyIntercalating dyesSewageGenome ViralReal-Time Polymerase Chain Reactionmedicine.disease_causeMicrobiologyMicrobiology03 medical and health sciencesCapsidbiology.animalmedicineAnimalsHumansColoring AgentsShellfishShellfish2. Zero hungerInfectivityComplex matrixbiologyViability PCRSewagebusiness.industryNorovirusRT-qPCRGeneral MedicineContamination6. Clean water3. Good health030104 developmental biologyCapsidNorovirusbusinessFood Science
researchProduct

Osteoradionecrosis of the jaws triggered by dental implant placement: a case report

2019

Background The decision-making process about how to rehabilitate edentulous osseous defects in patients with head and neck cancer history can be complex. Even though, endosseous dental implants could be considered to be the first choice for treating these patients, it is highly important to be aware of the complications that might occur. The aim of this report was to describe the clinical features of mandibular fracture after dental implants placement on a cancer irradiated patient and update the available information about this event. Case report The case describes a 70-year-old man, with medical background of radiotherapy in jaw bones to treat a carcinoma in the floor of the mouth and lat…

0301 basic medicinePathologic fractureOsteoradionecrosisCallus formationMandibular fracturemedicine.medical_treatmentDentistryCase ReportProsthesis03 medical and health sciences0302 clinical medicinestomatognathic systemmedicineCàncerGeneral DentistryCancerSoft palateImplants dentalsbusiness.industryDental implantsMandible030206 dentistry:CIENCIAS MÉDICAS [UNESCO]medicine.diseasestomatognathic diseasesmedicine.anatomical_structureUNESCO::CIENCIAS MÉDICAS030101 anatomy & morphologyImplantOral SurgerybusinessFractures
researchProduct

Growth and Osteogenic Differentiation of Discarded Gingiva-Derived Mesenchymal Stem Cells on a Commercial Scaffold

2020

Background In periodontal patients with jawbone resorption, the autologous bone graft is considered a "gold standard" procedure for the placing of dental prosthesis; however, this procedure is a costly intervention and poses the risk of clinical complications. Thanks to the use of adult mesenchymal stem cells, smart biomaterials, and active biomolecules, regenerative medicine and bone tissue engineering represent a valid alternative to the traditional procedures. Aims In the past, mesenchymal stem cells isolated from periodontally compromised gingiva were considered a biological waste and discarded during surgical procedures. This study aims to test the osteoconductive activity of FISIOGRAF…

0301 basic medicinePathologymedicine.medical_specialtyScaffoldperiodontal diseaseMatriderm®waste gingival tissueoral MSCsperiodontally compromised GMSCsRegenerative medicineBone resorptionSettore MED/13 - EndocrinologiaCell and Developmental Biology03 medical and health sciences0302 clinical medicineSettore MED/28 - Malattie OdontostomatologicheSettore BIO/13 - Biologia ApplicataBiopsymedicineFISIOGRAFT Bone Granular®Viability assaylcsh:QH301-705.5Original Researchautologous bone tissue regenerationmedicine.diagnostic_testCell growthbusiness.industryMesenchymal stem cellCell Biologyperiodontal disease bone resorption waste gingival tissue oral MSCs periodontally compromised GMSCs FISIOGRAFT Bone Granular R Matriderm R autologous bone tissue regenerationResorption030104 developmental biologylcsh:Biology (General)030220 oncology & carcinogenesisbusinessbone resorptionDevelopmental Biology
researchProduct

Release of copper-amended particles from micronized copper-pressure-treated wood during mechanical abrasion

2016

Background We investigated the particles released due to abrasion of wood surfaces pressure-treated with micronized copper azole (MCA) wood preservative and we gathered preliminary data on its in vitro cytotoxicity for lung cells. The data were compared with particles released after abrasion of untreated, water (0% MCA)-pressure-treated, chromated copper (CC)-pressure-treated wood, and varnished wood. Size, morphology, and composition of the released particles were analyzed. Results Our results indicate that the abrasion of MCA-pressure-treated wood does not cause an additional release of nanoparticles from the unreacted copper (Cu) carbonate nanoparticles from of the MCA formulation. Howev…

0301 basic medicinePreservativeCopper particlesAbrasion (mechanical)Cell SurvivalCytotoxicityIn vitro cytotoxicityBiomedical EngineeringNanoparticlechemistry.chemical_elementMedicine (miscellaneous)Pharmaceutical ScienceBioengineering010501 environmental sciences01 natural sciencesApplied Microbiology and BiotechnologyMass SpectrometryCell LineExposure03 medical and health sciencesPressureHumansCytotoxicity0105 earth and related environmental sciencesChemistryResearchtechnology industry and agricultureWaterCytotoxicity; Copper particles; Debris; Exposure; Inhalation; Wood dustMechanical abrasionCopperWood030104 developmental biologyInhalationA549 CellsMolecular MedicineNanoparticlesComposition (visual arts)DebrisReactive Oxygen SpeciesCopperWood dustNuclear chemistry
researchProduct

Asthmatics with high levels of serum surfactant protein D have more severe disease.

2016

Pulmonary surfactant is a mixture of lipids and surfactant-specific proteins that covers the alveolar surface, as well as the terminal conducting airways, lowering the surface tension at the air–liquid interface during breathing. The involvement of pulmonary surfactant in the pathophysiology of asthma has been suggested. An interesting working hypothesis is that the surface tension of the peripheral airways is altered in asthma, because the inflammatory process affects the structure and function of surfactant, leading to excessive airway narrowing and features of air trapping. We explored whether serum levels of surfactant protein D (SP-D) in asthmatics are related to the severity of the di…

0301 basic medicinePulmonary and Respiratory MedicineAdultMalesurfactantStatistics as TopicSevere diseasemacromolecular substancesSettore MED/10 - Malattie Dell'Apparato RespiratorioSeverity of Illness Index03 medical and health sciences0302 clinical medicineSeverity of illnessMedicineHumansAnti-Asthmatic Agentsbusiness.industrySmall airwaysSurfactant protein DReproducibility of Resultsrespiratory systemMiddle AgedPulmonary Surfactant-Associated Protein DAsthmaRespiratory Function Tests030104 developmental biology030228 respiratory systemImmunologyBiomarker (medicine)FemalebusinessBiomarkersThe European respiratory journal
researchProduct